This article is more than 5 years old. Information may no longer be current.
Mohs micrographic surgery may effectively treat rare hidradenocarcinoma
Mohs micrographic surgery was an effective long-term treatment for patients with hidradenocarcinoma, according to study results.
Researchers retrospectively evaluated the charts of patients with hidradenocarcinoma (HAC), a rare malignant adnexal neoplasm, treated with Mohs micrographic surgery (MMS) at the Mayo Clinic from 1993 to 2013. Data on patient demographics, tumor characteristics, MMS stages to clearance, follow-up, recurrence, metastasis and mortality were collected.
Ten patients (average age, 62.8 years; six women) with HAC had MMS performed during the study period. All 10 HAC cases were primary, with none having received prior treatment. Location of HACs included the occipital scalp (40%), extremities (30%) and cheek (20%). Lesions were clinically diagnosed to be a cyst in five of seven cases.
Preoperatively, patients’ average lesion size was 3.18 cm2. The researchers also observed an average of 1.5 MMS stages for clearance to occur, with all tumors cleared by two MMS stages or less.
Postoperative defect size was 8.77 cm2, with a mean follow-up duration of 7 years. There was no recurrence, metastasis or disease-related mortality associated the HAC cases treated with MMS, according to the researchers. – by Bruce Thiel
Disclosure: The researchers report no relevant financial disclosures.